Co-infection with hepatitis B does not alter treatment response in chronic hepatitis C

Clinics and Research in Hepatology and Gastroenterology

Volumn 37, Issue 5, 2013, Pages 485-490

  Uyanikoglu, Ahmet ^a   Akyuz, Filiz ^b   Baran, Bulent ^b   Simsek, Binnur Pinarbasi ^b   Ermis, Fatih ^c   Demir, Kadir ^b   Gulluoglu, Mine ^b   Badur, Selim ^b   Kaymakoglu, Sabahattin ^b  

^a HARRAN UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

^c DUZCE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; INTERFERON; PEGINTERFERON; PEGINTERFERON ALPHA2A; RIBAVIRIN; TENOFOVIR; VIRUS DNA; VIRUS RNA;

ACUTE HEPATITIS; ADULT; ANEMIA; ARTICLE; COHORT ANALYSIS; DRUG DOSE REDUCTION; DRUG FEVER; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; HEMODIALYSIS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MIXED INFECTION; SEROLOGY; SUSTAINED VIROLOGICAL RESPONSE; THROMBOCYTOPENIA; TREATMENT RESPONSE; VIRAL CLEARANCE; VIRUS REACTIVATION;

ANTIVIRAL AGENTS; COHORT STUDIES; DNA, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERFERONS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RIBAVIRIN; RNA, VIRAL; VIRAL LOAD; VIRUS REPLICATION;

EID: 84886947187     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2013.03.002     Document Type: Article

References (20)

1. Liaw Y.F. Role of hepatitis C virus in dual and triple hepatitis virus infection. Hepatology 1995, 22:1101-1108.
2. Crespo J., Lozano J.L., de la Cruz F., Rodrigo L., Rodriguez M., San Miguel G., et al. Prevalence and significance of hepatitis C viremia in chronic active hepatitis B. Am J Gastroenterol 1994, 89:1147-1151.
3. Liu C.J., Liou J.M., Chen D.S., Chen P.J. Natural course and treatment of dual hepatitis B virus and hepatitis C virus infections. J Formos Med Assoc 2005, 104:783-791.
4. Sagnelli E., Coppola N., Messina V., Di Caprio D., Marrocco C., Marotta A., et al. HBV superinfection in hepatitis C virus chronic carriers, viral interaction, and clinical course. Hepatology 2002, 36:1285-1291.
5. Sun C.A., Wu D.M., Lin C.C., Lu S.N., You S.L., Wang L.Y., et al. Incidence and cofactors of hepatitis C virus-related hepatocellular carcinoma: a prospective study of 12,008 men in Taiwan. Am J Epidemiol 2003, 157:674-682.
6. Crockett S.D., Keeffe E.B. Natural history and treatment of hepatitis B virus and hepatitis C virus coinfection. Ann Clin Microbiol Antimicrob 2005, 4:13.
7. Bellecave P., Gouttenoire J., Gajer M., Brass V., Koutsoudakis G., Blum H.E., et al. Hepatitis B and C virus coinfection: a novel model system reveals the absence of direct viral interference. Hepatology 2009, 50:46-55.
8. Raimondo G., Brunetto M.R., Pontisso P., Smedile A., Maina A.M., Saitta C., et al. Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus-coinfected patients. Hepatology 2006, 43:100-107.
9. Pugh R.N., Murray-Lyon I.M., Dawson J.L., Pietroni M.C., Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973, 60:646-649.
10. Bedossa P. Intraobserver, interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 1994, 20:15-20. The French METAVIR Cooperative Study Group.
11. Craxì A., Pawlotsky J.M., Wedemeyer H., Bjoro K., Flisiak R., Forns X., et al. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011, 55:245-264. EASL.
12. Chu C.J., Lee S.D. Hepatitis B virus/hepatitis C virus coinfection: epidemiology, clinical features, viral interactions and treatment. J Gastroenterol Hepatol 2008, 23:512-520.
13. Liu Z., Hou J. Hepatitis B virus (HBV) and hepatitis C virus (HCV) dual infection. Int J Med Sci 2006, 3:57-62.
14. Zarski J.P., Bohn B., Bastie A., Pawlotsky J.M., Baud M., Bost-Bezeaux F., et al. Characteristics of patients with dual infection by hepatitis B and C viruses. J Hepatol 1998, 28:27-33.
15. Sagnelli E., Pasquale G., Coppola N., Scarano F., Marrocco C., Scolastico C., et al. Influence of chronic coinfection with hepatitis B and C virus on liver histology. Infection 2004, 32:144-148.
16. Benvegnu L., Fattovich G., Noventa F., Tremolada F., Chemello L., Cecchetto A., et al. Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. A prospective study. Cancer 1994, 74:2442-2448.
17. Chiaramonte M., Stroffolini T., Vian A., Stazi M.A., Floreani A., Lorenzoni U., et al. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. Cancer 1999, 85:2132-2137.
18. Yu J.W., Sun L.J., Zhao Y.H., Kang P., Gao J., Li S.C. Analysis of the efficacy of treatment with peginterferon alpha-2a and ribavirin in patients coinfected with hepatitis B virus and hepatitis C virus. Liver Int 2009, 29:1485-1493.
19. Potthoff A., Wedemeyer H., Boecher W.O., Berg T., Zeuzem S., Arnold J., et al. The HEP-NET B/C co-infection trial: a prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection. J Hepatol 2008, 49:688-694.
20. Liu C.J., Chuang W.L., Lee C.M., Yu M.L., Lu S.N., Wu S.S., et al. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology 2009, 136:496-504. e493.